{"id":10980,"date":"2015-01-17T15:46:13","date_gmt":"2015-01-17T15:46:13","guid":{"rendered":""},"modified":"2015-01-17T15:46:13","modified_gmt":"2015-01-17T15:46:13","slug":"specific-active-immunotherapy-vegf-vaccine-patients-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/contenidosportal.sld.cu\/portal20142020\/2015\/01\/17\/specific-active-immunotherapy-vegf-vaccine-patients-advanced-solid-tumors\/","title":{"rendered":"Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors"},"content":{"rendered":"<div class=\"item-node\">\n<p><a href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X13016988\" target=\"_blank\" rel=\"noopener\">Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial<\/a><br \/>\nGavilondo JV, Hern&aacute;ndez-Bernal F, Ayala-&Aacute;vila M, de la Torre AV, de la Torre J, Morera-D&iacute;az Y y cols. del Grupo de Investigadores CENTAURO. <em>Vaccine<\/em> 2014;32(19):2241&ndash;50.<\/p>\n<p>El CIGB-247 es una nueva vacuna terap&eacute;utica contra el c&aacute;ncer que utiliza&nbsp; como ant&iacute;geno una variante humana de la mol&eacute;cula del factor de crecimiento endotelial vascular (VEGF, siglas en ingl&eacute;s), en combinaci&oacute;n con un adyuvante bacteriano.<\/p>\n<p>En ratas el CIGB-247 tiene efectos anti-tumorales y anti-metast&aacute;sicos. La vacuna induce la producci&oacute;n de anticuerpos anti-VEGF y una respuesta celular dirigida a c&eacute;lulas productoras de VEGF, y se ha comprobado que es segura en ratas, conejos y en primates no humanos.<\/p>\n<\/div>\n<div class=\"clear\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial Gavilondo JV, Hern&aacute;ndez-Bernal F, Ayala-&Aacute;vila M, de la Torre AV, de la Torre J, Morera-D&iacute;az Y y cols. del Grupo de Investigadores CENTAURO. Vaccine 2014;32(19):2241&ndash;50. El CIGB-247 es una nueva vacuna [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-10980","post","type-post","status-publish","format-standard","hentry","category-noticia"],"_links":{"self":[{"href":"https:\/\/contenidosportal.sld.cu\/portal20142020\/wp-json\/wp\/v2\/posts\/10980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/contenidosportal.sld.cu\/portal20142020\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/contenidosportal.sld.cu\/portal20142020\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/contenidosportal.sld.cu\/portal20142020\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/contenidosportal.sld.cu\/portal20142020\/wp-json\/wp\/v2\/comments?post=10980"}],"version-history":[{"count":0,"href":"https:\/\/contenidosportal.sld.cu\/portal20142020\/wp-json\/wp\/v2\/posts\/10980\/revisions"}],"wp:attachment":[{"href":"https:\/\/contenidosportal.sld.cu\/portal20142020\/wp-json\/wp\/v2\/media?parent=10980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/contenidosportal.sld.cu\/portal20142020\/wp-json\/wp\/v2\/categories?post=10980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/contenidosportal.sld.cu\/portal20142020\/wp-json\/wp\/v2\/tags?post=10980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}